News from BioLineRx A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-SMALL:BLRX,TelAviv:BLRX)

Mar 03, 2014, 16:35 ET
BIOLINERX Logo

BioLineRx Announces Underwritten Public Offering of its American Depositary Shares

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Feb 24, 2014, 07:00 ET
BIOLINERX Logo

BioLineRx Appoints Dr. Sandra Panem to Board of Directors

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Feb 12, 2014, 07:00 ET
BIOLINERX Logo

BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia

BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...

Feb 03, 2014, 07:00 ET
BIOLINERX Logo

BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Jan 23, 2014, 07:00 ET
BIOLINERX Logo

BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Jan 21, 2014, 07:00 ET
BIOLINERX Logo

BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Jan 13, 2014, 07:00 ET
BIOLINERX Logo

BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Jan 08, 2014, 07:00 ET
BIOLINERX Logo

BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Jan 07, 2014, 08:00 ET
BIOLINERX Logo

BioLineRx to Present at Biotech Showcase Conference in San Francisco

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Dec 18, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx Enters Clinic with Novel Treatment for Celiac Disease

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Dec 16, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...

Dec 10, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference

BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive preclinical results of BL-8040...

Nov 26, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment

 BioLineRx (NASDAQ: BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today additional Phase 2a results showing significant...

Nov 19, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today the publication of results showing that...

Nov 13, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx Reports Third Quarter 2013 Financial Results

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, today reported its results for the third quarter ending...

Nov 06, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx to Report Third Quarter 2013 Results on November 13, 2013

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its unaudited financial...

Nov 05, 2013, 09:00 ET
BIOLINERX Logo

BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013

 BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced that it will host an Analyst & Investor Day...

Nov 04, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has received regulatory approval from...

Oct 23, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes

 BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it has signed a worldwide, exclusive...

Oct 07, 2013, 07:00 ET
BIOLINERX Logo

BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BL-5010, a Novel Treatment for Removal of Skin Lesions

 BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today that a Notice of Allowance has been issued...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge